Temple Acquires Longevous to Enhance Wearable Health Technology

New Delhi, India Aug 27, 2026 ALN: Deepinder Goyal-backed Temple has acquired evidence-based Longevous as it builds its clinical and scientific capabilities ahead of its launch, Goyal announced the acquisition in a post on X on Thursday.

As part of the acquisition, London-headquartered Longevous founders Dr. Robert Mohr and Dr. Avi Roy, along with their team, will join Temple full-time. This strategic move is aimed at enhancing Temple's expertise in the burgeoning field of wearable health technology, which has gained significant traction as consumers increasingly seek to monitor and improve their health through innovative devices.

Dr. Robert Mohr has been appointed Chief Medical Officer at Temple. He is a board-certified physician with nearly two decades of clinical experience and previously worked in emergency medicine before moving into evidence-based longevity medicine. His extensive background in clinical practice equips him with a unique perspective on patient care, which is essential for developing technologies that are not only innovative but also practical and effective for real-world applications.

Dr. Avi Roy has joined as Head of Science. He is an Oxford-trained biomedical scientist and has worked at the intersection of longevity science and business. His experience includes co-founding Founders Health and UDA, as well as serving as a research fellow at the Centre for the Advancement of Sustainable Medical Innovation at the University of Oxford. Roy's expertise in both the scientific and commercial aspects of health technology is expected to play a crucial role in Temple's development strategy.

According to Goyal, Mohr and Roy had been testing Temple for two months and worked with its science team to pressure-test its Entropy technology and the data it collects. They also became involved in Temple’s validation work and reviewed its first scientific manuscripts before submission. This collaborative effort underscores the importance Temple places on rigorous scientific validation as it prepares to launch its wearable technology. Such validation is crucial in the health tech industry, where consumers and healthcare providers alike demand evidence-based solutions that can demonstrably improve health outcomes.

Longevous will continue to operate as part of Temple, while Mohr and Roy will continue to look after its existing clients personally, Goyal said in his tweet. This continuity is likely to reassure Longevous's current clientele, who may be concerned about the transition and the future of the services they rely on. Maintaining existing client relationships while integrating into a larger organization is often a delicate balance, but it can also lead to enhanced offerings through combined resources and expertise.

Founded by Goyal in 2024, Temple is preparing for its launch with wearable technology to track physiological and health signals, while building an in-house science team focused on longevity. The wearable health technology market has been expanding rapidly, driven by advancements in sensor technology, data analytics, and a growing consumer interest in personal health management. This acquisition positions Temple to leverage Longevous's expertise in longevity science, which is increasingly recognized as a critical component of health technology.

The implications of this acquisition extend beyond just the immediate benefits to Temple. As the health tech landscape continues to evolve, companies that can effectively integrate clinical insights with innovative technology are likely to lead the market. The convergence of healthcare and technology is not just about developing new devices; it is also about understanding how these devices can be used to enhance health outcomes, manage chronic conditions, and promote longevity.

Moreover, the focus on evidence-based practices in longevity medicine reflects a broader trend in healthcare towards personalized medicine. As consumers become more health-conscious and proactive about their well-being, there is a growing demand for solutions that are tailored to individual health needs. Temple's strategic direction, particularly with the integration of Longevous's expertise, suggests that the company is committed to meeting these demands through rigorous scientific research and development.

In the context of the global health landscape, the acquisition of Longevous by Temple also highlights the increasing importance of longevity as a field of research and application. With an aging population and rising healthcare costs, there is a pressing need for solutions that can help individuals maintain their health and vitality as they age. Longevity science aims not only to extend lifespan but also to enhance healthspan—the period of life spent in good health. This dual focus is critical for developing technologies that are not only innovative but also sustainable and beneficial for society as a whole.

As Temple moves forward with its plans, the integration of Longevous's team will likely accelerate its development timeline and enhance its ability to deliver cutting-edge wearable health technologies. The collaboration between experienced clinicians and scientists is expected to yield products that are not only technologically advanced but also grounded in clinical reality, ultimately benefiting users who are looking for reliable tools to support their health journeys.

In conclusion, the acquisition of Longevous by Temple marks a significant step in the evolution of wearable health technology. By combining clinical expertise with innovative technology, Temple is positioning itself to play a pivotal role in the future of health management, particularly in the context of longevity and personalized healthcare solutions. As the company prepares for its launch, stakeholders in the health tech industry will be watching closely to see how this integration unfolds and what it means for the future of health technology.